RIGHTS ISSUE
Home
Company
About us
Management
Board of Directors
Scientific Advisory Board
Partnerships
Partnerships
Nox Science
NOX Enzymes
NADPH Oxidase
NOX Enzyme Family
NOX Expression
NOX and Disease
Oxidative Stress and Disease
Physiological Functions of NOX
Fibrotic diseases
Neurodegenerative diseases
Cardiovascular diseases
Publications
Pipeline
Setanaxib
Preclinical NOX1 program
Research programs
Investors
Stock information
Analyst coverage
Contribution project
Press release
Project presentation
Documentation
Shareholders general meeting
Press releases
2020
2019
2018
2017
2016
2015
2014
Events and presentations
Regulated information
Financial information
2020
2019
2018
2017
2016
2015
2014
Other regulated information
2020
2019
2018
2017
2016
2015
2014
Governance
OCABSA warrants
Shareholder information
Shareholders’ meetings
2020
2019
AGM of June 13, 2019
AGE of January 2019
2018
AGM of june 13, 2018
2017
AGM of June 15, 2017
AGM of February 28, 2017
2016
2015
2014
Agenda
News and Events
Press releases
Events and presentations
Media
Press clippings
Interviews
Contacts
RIGHTS ISSUE
News
See all news
Prev
Next
2020-03-03 - 18:38
Genkyotex’s setanaxib significantly improves immunotherapy including...
2020-02-27 - 18:00
Genkyotex announces 2019 annual financial results and provides corpora...
2020-02-04 - 17:45
Genkyotex announces its financial calendar for 2020
2020-01-16 - 19:30
Genkyotex provides business update and reports gross cash position at ...
2020-01-13 - 17:00
Half-yearly report on Genkyotex’s liquidity contract with Kepler Che...
2019-12-03 - 07:00
Genkyotex reports progress of Setanaxib phase 2 investigator initiated...
2019-10-24 - 18:00
Genkyotex provides business update and reports cash position at Septem...
2019-09-19 - 18:00
Genkyotex Announces First Half 2019 Results
Events
See all events
Prev
Next
2020-02-04 - 11:00
Investor Presentation February 2020
2019-07-25 - 13:30
Conference call July 25 2019 – Inhibiting NOX enzymes to treat ...
2019-07-24 - 19:00
Genkyotex conference call on July 25, 2019 at 2 pm CEST
2019-07-03 - 12:00
Genkyotex invitation to Biotech Agora in Paris on July 10, 2019
2019-05-02 - 13:00
Phase 2 trial of GKT831 in patients with primary biliary cholangitis ...
2019-04-24 - 14:00
ILC2019 Presentation – GKT831 Phase 2 in PBC
2018-11-05 - 15:00
Management presentation on positive interim Phase 2 results in PBC
